trades in the stock market as ticker CLDA. Business Summary & Profile For .
|Blend Therapeutics Appoints Drew Fromkin as President and Chief Executive Officer
||13 Apr 2015
|[Business Wire] - Blend Therapeutics, Inc., a biopharmaceutical company discovering and developing two distinct classes of targeted anti-cancer medicines to advance the treatment of patients with solid tumor cancers, announced today the appointment of Drew Fromkin as President and Chief Executive Officer and a member of the company’s Board of Directors.
Get our Stock Market & financial investment news alerts in your inbox
Quotes are delayed for NASDAQ, NYSE, OTC, OTCBB (Penny Stocks) and NYSE Amex when available. Quotes and other information supplied by independent providers and feeds. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither
Localnewsnor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing
Localnews, you agree not to redistribute the information found therein.
Localnews is committed to protecting the privacy of all our visitors and subscribers. Your right to privacy is very important to us. When you choose to provide us with information about yourself, we recognize that you trust us to act in a responsible manner. SHARING OF INFORMATION -
Localnews does not sell, rent, lease or share any user information that it has collected over this website.